The US Conference on Rare Diseases and Orphan Products will provide a forum to address the need for effective therapies for rare diseases.
Horsham ,PA, USA (PRWEB) September 15, 2011
DIA and the National Organization for Rare Disorders (NORD), in collaboration with, EURORDIS, National Institutes of Health (NIH), US Food and Drug Administration (FDA), and the Duke Department of Pediatrics at the Duke University School of Medicine, will host the US Conference on Rare Diseases and Orphan Products from October 11-13 in Washington, DC.
In addition to high-level plenary sessions, the conference will feature three parallel tracks specifically developed for researchers and drug and device companies, patient advocates and patient organizations, and investors. Topics will include:
- Researchers, Drug and Device Companies
o NIH grant and FDA approval requirements
o Development of orphan products and how to avoid common pitfalls
o Grants to orphan designation and clinical development to product approvals
- Patient Advocates and Patient Organizations
o How to become a more effective advocate for the patients you represent
o New and emerging federal policies that affect patients with rare diseases
o How the government and private sectors are addressing the special challenges faced by patients in the new health care environment
o Ways to run patient organizations efficiently and creatively for effective advocacy
o Venture philanthropy and how it will affect research funding
o FDA and NIH interaction with the drug and device development processes
o De-risking investments in orphan products and timelines for research and regulatory reviews
“DIA is honored to partner with the most prestigious organizations in the world to host this first annual conference on rare diseases and orphan products,” says DIA Executive Director Paul Pomerantz. “This event brings together academic and clinical researchers, pharmaceutical and biotechnology companies, regulatory and health agencies, patient organizations, and payers to address the need for effective therapies for rare diseases.”
- Michael J. Astrue, JD, Commissioner, Social Security Administration
- Francis S. Collins, MD, PhD, Director, NIH
- John F. Crowley, Chairman and CEO, Amicus Therapeutics
- Fred Hassan, MBA, Partner, Warburg Pincus; Chairman of the Board, Bausch + Lomb
- Mark B. McClellan, MD, PhD, Director, Engelberg Center for Health Care Reform, The Brookings Institution
- Frank J. Sasinowski, MS, MPH, JD, Director, Hyman Phelps & McNamara
- Jeffrey Shuren, MD, JD, Director, Center for Devices and Radiological Health, FDA
- Janet Woodcock, MD, Director, Center for Drug Evaluation and Research, FDA
“The US Conference on Rare Diseases and Orphan Products will provide a forum to address the need for effective therapies for rare diseases,’” explains Peter Sontenstall, President and CEO, National Organization for Rare Disorders (NORD). “Through this dialogue, we hope to facilitate accelerated development of new therapies and improved access to existing therapies for rare diseases.”
Register for US Conference on Rare Diseases and Orphan Products.
Follow on Twitter using #orphanproducts.
DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well being worldwide. Headquarters are in Horsham, Pa., USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India and Beijing, China.
Contact: Joe Krasowski
Marketing Communications Manager